Ausgabe 1/2011
Inhalt (30 Artikel)
Review on clinical trials of targeted treatments in malignant mesothelioma
Jan Nyrop Jakobsen, Jens Benn Sørensen
Cryptotanshinone has diverse effects on cell cycle events in melanoma cell lines with different metastatic capacity
Lei Chen, Shi-zhong Zheng, Zhi-guang Sun, Ai-yun Wang, Chen-hu Huang, Neville A. Punchard, Shi-le Huang, Xiang Gao, Yin Lu
Can localised 19F magnetic resonance spectroscopy pharmacokinetics of 5FU in colorectal metastases predict clinical response?
Dominick J. O. McIntyre, Franklyn A. Howe, Christophe Ladroue, Fiona Lofts, Marion Stubbs, John R. Griffiths
Pegylated liposomal doxorubicin, 5-fluorouracil and cisplatin versus mitomycin-C, 5-fluorouracil and cisplatin for advanced gastric cancer: a randomized phase II trial
Stefano Cascinu, Eva Galizia, Roberto Labianca, Francesco Ferraù, Francesca Pucci, Rosa Rita Silva, Gabriele Luppi, Giordano Domenico Beretta, Rossana Berardi, Mario Scartozzi
In vitro and in vivo antitumor effects of (4-methoxyphenyl)(3,4,5-trimethoxyphenyl)methanone
Hemerson Iury F. Magalhães, Daniel P. Bezerra, Bruno C. Cavalcanti, Diego V. Wilke, Rodrigo Rotta, Dênis P. de Lima, Adilson Beatriz, Ana Paula N. N. Alves, Flávio da S. Bitencourt, Ingrid S. T. de Figueiredo, Nylane M. N. Alencar, Letícia V. Costa-Lotufo, Manoel Odorico Moraes, Claudia Pessoa
Pharmacokinetic results of a phase I trial of sorafenib in combination with dacarbazine in patients with advanced solid tumors
Erich Brendel, Matthias Ludwig, Chetan Lathia, Caroline Robert, Stanislas Ropert, Jean-Charles Soria, Jean-Pierre Armand
Α multicenter phase II study of pegylated liposomal doxorubicin in combination with irinotecan as second-line treatment of patients with refractory small-cell lung cancer
Nikolaos Xenidis, Nikolaos Vardakis, Ioannis Varthalitis, Stylianos Giassas, Emmanouel Kontopodis, Nikolaos Ziras, Ioannis Gioulbasanis, George Samonis, Kostas Kalbakis, Vassilis Georgoulias
Efficacy and safety of motesanib, an oral inhibitor of VEGF, PDGF, and Kit receptors, in patients with imatinib-resistant gastrointestinal stromal tumors
Robert S. Benjamin, Patrick Schöffski, Jörg Thomas Hartmann, Allan Van Oosterom, Binh Nguyen Bui, Justus Duyster, Scott Schuetze, Jean-Yves Blay, Peter Reichardt, Lee S. Rosen, Keith Skubitz, Sheryl McCoy, Yu-Nien Sun, Daniel E. Stepan, Laurence Baker
Kinase activation profile associated with TGF-β-dependent migration of HCC cells: a preclinical study
Emilia Fransvea, Antonio Mazzocca, Angela Santamato, Amalia Azzariti, Salvatore Antonaci, Gianluigi Giannelli
Interleukin-1 receptor antagonist reduced apoptosis and attenuated intestinal mucositis in a 5-fluorouracil chemotherapy model in mice
Zhen-Qian Wu, Xiao-Dong Han, Yu Wang, Ke-Li Yuan, Zhi-Ming Jin, Jian-Zhong Di, Jun Yan, Ye Pan, Pin Zhang, Xin-Yu Huang, Zhi-Gang Wang, Qi Zheng
Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868
Lars Petter Jordheim, Adriana Plesa, Michel Dreano, Emeline Cros-Perrial, Céline Keime, Stéphanie Herveau, Delphine Demangel, Julie A. Vendrell, Charles Dumontet
Hyaluronic acid–paclitaxel: effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts
Ilaria De Stefano, Alessandra Battaglia, Gian Franco Zannoni, Maria Grazia Prisco, Andrea Fattorossi, Daniele Travaglia, Silvia Baroni, Davide Renier, Giovanni Scambia, Cristiano Ferlini, Daniela Gallo
Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells
Anja Wilmes, David O’Sullivan, Ariane Chan, Clarissa Chandrahasen, Ian Paterson, Peter T. Northcote, Anne Camille La Flamme, John H. Miller
Novel small molecule drugs inhibit tumor cell metabolism and show potent anti-tumorigenic potential
Christina Trojel-Hansen, Kamille Dumong Erichsen, Mette Knak Christensen, Peter Buhl Jensen, Maxwell Sehested, Søren Jensby Nielsen
Multimodal therapy for liver cirrhosis patients with advanced hepatocellular carcinoma
Hidenari Nagai, Teppei Matsui, Masahiro Kanayama, Noritaka Wakui, Kouichi Momiyama, Manabu Watanabe, Yoshinori Igarashi, Yasukiyo Sumino
Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosis
Kurt Van der Speeten, O. Anthony Stuart, David Chang, Haile Mahteme, Paul H. Sugarbaker
A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer
Masashi Kanai, Kenichi Yoshimura, Masanori Asada, Atsushi Imaizumi, Chihiro Suzuki, Shigemi Matsumoto, Takafumi Nishimura, Yukiko Mori, Toshihiko Masui, Yoshiya Kawaguchi, Kazuhiro Yanagihara, Shujiro Yazumi, Tsutomu Chiba, Sushovan Guha, Bharat B. Aggarwal
Prognostic implication of 18F FDG-PET in patients with extrahepatic metastatic hepatocellular carcinoma undergoing systemic treatment, a retrospective cohort study
Dong-Yeop Shin, Sae-Won Han, Do-Youn Oh, Seock-Ah Im, Tae-You Kim, Yung-Jue Bang
Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer
Jung A. Kim, Jeeyun Lee, Boram Han, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang
Difluorodeoxyuridine plasma concentrations after low-dose gemcitabine during chemoradiation in head and neck cancer patients
P. Specenier, G. Guetens, J. Dyck, G. De Boeck, J. Weyler, D. Van den Weyngaert, K. Aelbrecht, J. B. Vermorken
Preclinical toxicity and toxicokinetics of GTI-2040, a phosphorothioate oligonucleotide targeting ribonucleotide reductase R2
Eckhardt S. Ferdinandi, Aikaterini Vassilakos, Yoon Lee, Jeff Lightfoot, Dimitri Fitsialos, Jim A. Wright, Aiping H. Young
Lentivirus-mediated inhibition of Med19 suppresses growth of breast cancer cells in vitro
Li-Hua Li, Jie He, Dong Hua, Zi-Jian Guo, Qi Gao
Salvage treatment in metastatic breast cancer with weekly paclitaxel and bevacizumab
Aris Polyzos, Kostas Kalbakis, Nikolaos Kentepozidis, Stylianos Giassas, Antonia Kalykaki, Nikolaos Vardakis, Vasiliki Bozionelou, Emmanouel Saloustros, Emmanouel Kontopodis, Vassilis Georgoulias, Dimitris Mavroudis
Sandostatin desensitization–a strategy useful for patients with carcinoid tumors, intolerant to sandostatin
Sanjay Vinjamaram, Renuka Iyer
Inhibition of N-linked glycosylation by tunicamycin induces E-cadherin-mediated cell–cell adhesion and inhibits cell proliferation in undifferentiated human colon cancer cells
Julio Cesar Madureira de Freitas Junior, Bárbara Du Rocher D’Aguiar Silva, Waldemir Fernandes de Souza, Wallace Martins de Araújo, Eliana Saul Furquim Werneck Abdelhay, José Andrés Morgado-Díaz
High-performance liquid chromatographic method for the determination of sorafenib in human serum and peritoneal fluid
Werner J. Heinz, Kathrin Kahle, Annegret Helle-Beyersdorf, Diana Schirmer, Ulrike Lenker, Daniela Keller, Peter Langmann, Hartwig Klinker
Phase I clinical trial of hepatic arterial infusion of paclitaxel in patients with advanced cancer and dominant liver involvement
Apostolia M. Tsimberidou, Katherine Letourneau, Siqing Fu, David Hong, Aung Naing, Jennifer Wheler, Cynthia Uehara, Stephen E. McRae, Sijin Wen, Razelle Kurzrock
Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
Taekyu Lim, Jeeyun Lee, Duk Joo Lee, Ha Yeon Lee, Boram Han, Kyung Kee Baek, Hee Kyung Ahn, Su Jin Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Kyoung-Mee Kim, Won Ki Kang
Pharmacokinetics of oxaliplatin in a hemodialytic patient treated with modified FOLFOX-6 plus bevacizumab therapy
Takahiro Horimatsu, Shin’ichi Miyamoto, Shuko Morita, Yoko Mashimo, Yasumasa Ezoe, Manabu Muto, Tsutomu Chiba
Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study
Francisco C. Muñoz-Casares, Sebastián Rufián, Álvaro Arjona-Sánchez, María J. Rubio, Rafael Díaz, Ángela Casado, Álvaro Naranjo, Carlos J. Díaz-Iglesias, Rosa Ortega, María C. Muñoz-Villanueva, Jordi Muntané, Enrique Aranda